• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Replicel prototypes its next-gen dermal injector

September 8, 2017 By Sarah Faulkner

Replicel injectorRepliCel Life Sciences (OTC:REPCF) said yesterday that it has developed prototypes of its RCI-02 motorized injection device designed with programmable depth and volume, as well as interchangeable needle head configurations.

The injector was built to deliver an array of substances, including dermal fillers, drugs, cells or biologics intradermally, subcutaneously or intramuscularly.

The company said it hopes to use its functional prototypes to gather feedback from dermatologists, design clinical trials to assess the device and prepare for an anticipated launch in the European market next year.

Replicel reported that one near-term commercial opportunity for RCI-02 is to improve the injection of hyaluronic acid-based dermal fillers.

“As a practicing dermatologist and a co-founder of RepliCel, I am thrilled to see the functioning prototypes,” chief medical officer Dr. Rolf Hoffman said in prepared remarks. “We are excited to begin exploring the clinical applications of this device with our global network of dermatology experts.”

Data from functional testing of the RCI-02 prototypes will help the company prepare an application for CE Mark clearance in the European Union, Replicel said.

“Hitting this milestone confirms we are on track with this product’s commercialization schedule, which involves us getting the device market-ready and in the hands of a commercial partner,” president & CEO, R. Lee Buckler added. “This is the landmark milestone we’ve been waiting for to mature ongoing partnership discussions into negotiations and deal execution.”

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Drug-Device Combinations, Featured, Orthopedics, Pharmaceuticals, Wall Street Beat Tagged With: RepliCel Life Sciences

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS